These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 23831232)

  • 1. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.
    Guiu S; Arnould L; Bonnetain F; Dalban C; Favier L; Desmoulins I; Créhange G; Coutant C; Fumoleau P; Coudert B
    Breast; 2013 Jun; 22(3):301-8. PubMed ID: 22863283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
    Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
    Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
    Cabuk D; Basaran G; Teomete M; Dane F; Korkmaz T; Seber S; Telli F; Yumuk PF; Turhal S
    Asian Pac J Cancer Prev; 2014; 15(1):117-22. PubMed ID: 24528011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
    Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
    Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
    Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
    Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
    Niwińska A; Tacikowska M; Murawska M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer brain metastases - A 12 year review of treatment outcomes.
    De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
    Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
    Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
    Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems.
    Viani GA; Castilho MS; Salvajoli JV; Pellizzon AC; Novaes PE; Guimarães FS; Conte MA; Fogaroli RC
    BMC Cancer; 2007 Mar; 7():53. PubMed ID: 17386108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
    Yomo S; Hayashi M; Cho N
    J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.